Biogen (BIIB) Getting Somewhat Positive Press Coverage, Report Finds
News coverage about Biogen (NASDAQ:BIIB) has trended somewhat positive on Wednesday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Biogen earned a news impact score of 0.13 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.6831792629143 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Biogen Inc. (BIIB) Shares Bought by Stoneridge Investment Partners LLC (techkenyot.com)
- Biogen Inc. (BIIB) Position Decreased by Schwab Charles Investment Management Inc (topactu.net)
- Biogen Inc (NASDAQ:BIIB) Posts New Data from Phase Ib Trial Of Aducanumab (mmjreporter.com)
- Biogen's Alzheimer's Drug Shows Promise — Could It Break Out? (finance.yahoo.com)
- A Few Positives and Negatives For Fortinet, Inc. (FTNT), Biogen Inc … – AllStockNews (allstocknews.com)
A number of brokerages have recently weighed in on BIIB. UBS AG reaffirmed a “neutral” rating and set a $285.00 price target (up previously from $270.00) on shares of Biogen in a report on Wednesday, July 26th. Sanford C. Bernstein reissued an “outperform” rating on shares of Biogen in a research note on Thursday, May 25th. Vetr downgraded shares of Biogen from a “strong-buy” rating to a “buy” rating and set a $311.67 price objective for the company. in a research note on Wednesday, June 21st. Goldman Sachs Group, Inc. (The) raised shares of Biogen from a “buy” rating to a “conviction-buy” rating and set a $338.00 price objective for the company in a research note on Wednesday, August 16th. Finally, Deutsche Bank AG reissued a “buy” rating and issued a $319.00 price objective (up previously from $315.00) on shares of Biogen in a research note on Wednesday, July 26th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $328.81.
Shares of Biogen (NASDAQ BIIB) opened at 293.58 on Wednesday. Biogen has a 12-month low of $244.28 and a 12-month high of $304.23. The firm has a 50-day moving average of $284.39 and a 200-day moving average of $274.87. The firm has a market capitalization of $62.07 billion, a PE ratio of 19.27 and a beta of 0.79.
Biogen (NASDAQ:BIIB) last posted its earnings results on Tuesday, July 25th. The biotechnology company reported $5.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.36 by $0.68. Biogen had a return on equity of 37.42% and a net margin of 28.10%. The company had revenue of $3.08 billion for the quarter, compared to analyst estimates of $2.81 billion. During the same quarter in the previous year, the firm earned $5.21 earnings per share. The firm’s quarterly revenue was up 6.4% compared to the same quarter last year. Equities analysts anticipate that Biogen will post $21.44 earnings per share for the current year.
In other Biogen news, EVP Susan H. Alexander sold 4,974 shares of Biogen stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $290.01, for a total value of $1,442,509.74. Following the transaction, the executive vice president now owns 22,258 shares in the company, valued at $6,455,042.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brian S. Posner sold 1,084 shares of Biogen stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $256.31, for a total value of $277,840.04. Following the completion of the transaction, the director now owns 6,330 shares in the company, valued at approximately $1,622,442.30. The disclosure for this sale can be found here. Insiders sold 13,816 shares of company stock worth $3,931,380 in the last quarter. 0.32% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.watchlistnews.com/biogen-biib-getting-somewhat-positive-press-coverage-report-finds/1530538.html.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.